Most Popular

February 05, 2024 | Monday

Dubai Health unveils Medlab Middle East 2024, region’s largest laboratory exhibition and congress

Medlab Middle East was innaugrated on 5th Feb at the Dubai World Trade Centre by H.H. Sheikh Mansoor bin Mohammed bin Rashid Al Maktoum, Vice Chairman of Dubai Health. The region’s largest laboratory exhibition and congress convened more than 900 exhibiting companies and 30,000 attendees from worldwide. The event plays a vital role in advancing the field of laboratory medicine in the region and worldwide. Medlab Middle East will take place from 5 – 8 February 2024 at the Dubai World Trade Centre, Dubai, UAE. A digital event will occur from 22 January – 22 February 2024. As the MENA region's most prominent medical laboratory exhibition and congress, Medlab Middle East plays a crucial role in developing the value of laboratory medicine in reshaping the future of diagnostics by providing a platform for laboratory industry leaders, including manufacturers, dealers and distributors, to share best practice, showcase innovations, collaborate and network.   The Conference and Exhibition Pavillions: The 2024 edition will feature over 900 exhibiting companies from more than 40 countries, showcasing the latest laboratory innovations across eight product categories, which include Disposables and Consumer Goods, Emergency Medicine, Imaging and Diagnostics, Healthcare and General Services, IT, Laboratory, Medical Equipment and Devices and Pharma and Nutrition.  Underscoring Medlab Middle East’s commitment to innovation, a new NextGen Medicine Zone and Conference have been added to the exhibition this year in partnership with Bahrain-based EXPRESSMED Diagnostics and Research. The NextGen Medicine zone occupies 1,500 sqm of exhibition space and features over 100 exhibitors, while a new NextGen Medicine track has been added to the Medlab Middle East Congress. Medlab Middle East Congress is the region’s only multi-disciplinary congress and provides 12 CME-accredited live in-person conferences led by more than 130 laboratory industry experts from around the world. Running throughout the four-day exhibition, conference tracks include NextGen Medicine, Laboratory Management, Lab Quality Management, Clinical Chemistry, Immunology, Haematology, Clinical Microbiology, Clinical Genomic Interpretation, Blood Transfusion Medicine, Histopathology, Future of Lab and Sustainability in the Lab. Medlab Middle East takes place in Za’abeel Halls 1-7 at the Dubai World Trade Centre and will showcase global manufacturers and established laboratory suppliers. Brands showcased include Abbott, Beckman Coulter, Purelab and the Gulf Scientific Corporation.   Think Tank:  In addition, Medlab Middle East, growth strategy consulting firm Frost & Sullivan hosted a Think Tank on the ‘Strategic Investments and Growth Opportunities: Reshaping the Future of Laboratories and Diagnostics Industry in the Middle East’.  Attended by representatives from Abbott, Randox, Thermo Fisher Scientific and Cleveland Clinic, the distinguished panel of healthcare leaders addressed industry topics including the key drivers and challenges for the laboratories and diagnostics sectors in the Middle East, and which technologies are expected to drive growth in the industry in the years ahead.  Dr Bernie Croal, President-Elect of The Royal College of Pathologists in the UK discussed ‘strategies to ensure that lab testing is focused and safe’ at the Laboratory Management Conference, while Dr Lubna AlZadjali, Consultant Hematopathologist from the Sultan Qaboos Comprehensive Cancer Centre in Muscat, spoke at the Haematology Conference on Haematology laboratory information systems.  Tom Coleman, Senior Exhibition Director, Medlab Series, Informa Markets said: “Last year was a record-breaking year for Medlab Middle East, where AED1.9 billion of deals were secured. Following on from this success, we are expecting a 20% increase in visitor numbers this year, with an estimated 30,000 attendees, and we have some exciting new additions to the event which will elevate opportunities for knowledge-sharing and business-building even further.”

February 06, 2024 | Tuesday

Transformative potential of Artificial Intelligence (AI) on the laboratory sector

The healthcare industry around the world is increasingly adopting Artificial Intelligence (AI) to accelerate scientific advancements, develop new treatments and improve health outcomes across a diverse spectrum of health conditions. Medlab Middle East is poised to delve into the pivotal role of AI in laboratories when global experts gather at the event from 5-8 February at the Dubai World Trade Centre. The use of AI in medical imaging is gaining traction across the UAE, supported by a number of government initiatives and policies. Several healthcare organisations in Dubai are successfully using AI-based medical imaging technology, and the Abu Dhabi Health Services Company (SEHA) has adopted AI-based medical imaging technology for the automated detection of breast cancer and lung diseases. In October, Saudi Arabia announced the country’s first AI-powered eye screening tests which can provide accurate diagnosis of diabetic retinopathy, simplify screening and save time and costs. AI is also helping to speed up the discovery of new medicines, a process which typically involves the testing of various chemical compounds – of which there can be millions. AI will perform trial and error within a computer and come up with the best combination for the drug. According to Data Bridge Market Research, the global AI in drug discovery market is expected to reach $24.7 million by 2029, growing at a rate of 53.3% annually. Professor Hassan Ugail, Director of the Centre for Visual Computing and Intelligent Systems at the University of Bradford in the UK, spoke at Medlab Midde East as part of the ‘Digitalisation, Automation and Innovation’ session, on the second day of the NextGen Conference. Professor Ugail has led the development of a pioneering AI tool called “OrQA” (Organ Quality Assessment), which assesses the quality of human organs for transplantation. When it comes to evaluating organs for transplantation, time is a critical factor, and OrQA can provide detailed and reliable analysis in a matter of seconds. The AI method uses a scoring system to grade an organ between zero and five, with organs that score below four, being suitable for use.  Professor Ugail explains: “We use state-of-the-art artificial intelligence techniques to train a machine learning algorithm and worked with a number of surgeons to ‘score’ a range of organs. The machine then learns about the scores, alongside other characteristics such as the colour, texture and shape of the organ. He adds: “Traditionally when an organ becomes available for transplantation, you need to gather experts as quickly as possible for an assessment. With OrQA, an image of that organ can be uploaded and it will quickly provide a score. It is an excellent application of AI for real healthcare use and helps surgeons to make the best possible decisions in the quickest possible time.” Funded by the UK’s National Institute for Health and Care Research (NIHR), the £1.2 million project is a collaboration between the University of Bradford, Newcastle University and the University of Oxford and could result in an additional 200 patients receiving life-saving kidney transplants and 100 more liver transplants per year, potentially saving millions of pounds for the UK National Health Service (NHS). There are plans to take the tool worldwide in the coming year. In October 2023, the UAE announced the launch of its first Centre for Excellence (COE) for artificial intelligence. One of the services provided by the COE is an organ donation and transplant centre. This facility helps to match donors and patients by analysing test results, which helps to facilitate organ transplants and prioritise critical cases within and outside the country. Additionally, AI technology will be used to analyse the results of radiological scans, which is expected to increase the efficiency of diagnoses. The Centre is set to launch an AI lab in the coming weeks. Tom Coleman, Exhibition Director, Informa Markets Healthcare concludes: “The integration of AI into laboratory practices is already redefining the landscape of scientific discovery and driving innovation in healthcare. In the years to come, the need for AI in medical imaging will continue to grow. AI technologies are able to process and analyse data more quickly and accurately leading to new insights in various realms of study, and we are excited to spotlight this exciting field of healthcare at Medlab Middle East.”

February 07, 2024 | Wednesday

UltraSight & Selvas Healthcare to commercialise AI-powered cardiac ultrasound software in Asia

Israel-based UltraSight, a digital health pioneer transforming cardiac imaging through the power of artificial intelligence (AI), has announced a partnership with Selvas Healthcare (subsidiary of Selvas Group), a Korean-based global digital healthcare company with innovative technology in medical device manufacturing and software. This new joint venture kicks off the introduction of UltraSight's real-time AI guidance technology in Asia, beginning with the regulatory process for approvals that may lead to eventual commercialization and distribution in Korea and the Southeast Asian market. UltraSight CEO Davidi Vortman said, "We aim to address the significant global disparity between the number of cardiovascular disease patients and the availability of cardiac ultrasound. Having already entered the market in the US, we look forward to embarking on this new venture with SELVAS Healthcare and bringing the benefits of our cardiac imaging technology to Korea, with a long-term vision of expanding UltraSight's footprint throughout Asia." UltraSight's software pairs with point-of-care ultrasound (POCUS) devices to provide medical professionals with real-time guidance to acquire diagnostic-quality cardiac ultrasound images, regardless of experience level. Selvas Healthcare will have exclusive rights to distribute and commercialize UltraSight's AI cardiac ultrasound technology in Korea.  

February 05, 2024 | Monday

"It's the time for the GCC to implement a societal approach to achieve healthy longevity" says Health trailblazer

Dr Mehmood Khan, CEO of Hevolution Foundation, a trailblazer in healthcare and longevity, has urged the healthcare community in the region to address the future issues posed by the ageing population now and implement an all-of-society approach to achieve healthy longevity, during his opening remarks at Arab Health’s Future Health Summit held today at the Museum of the Future. Highlighting healthspan, the period people stay healthy, and lifespan, the period where people live longer, Dr Khan revealed the global average of years spent in poor health is 9.7 years, underscoring the importance of addressing this challenge and ensuring those in later life remain independent, cognitive, functional, and contribute directly or indirectly to communities they live in.                Speaking at the session Bridging the Gap Between Lifespan and Healthspan, Dr Khan said: “The MENA population most at risk for noncommunicable diseases (NCDs) is those over 60 years. Adult obesity is becoming a significant issue and risk factor, and cardiovascular disease, cancer, and diabetes represent up to one-third of the disease burden in the region. Because the population is relatively young, now is the time to rethink our public health approach to address these future challenges. “If we can intervene in ageing, society would reap substantial benefits. From reactive amelioration to proactive prevention, we can diminish vulnerability to future disability for the ageing population, reduce the infirmities of old age, increase individual productivity, and decrease healthcare costs globally.  Compressing morbidity by 12 months could generate $40 trillion annually in healthcare cost savings and productivity increases.” Other speakers at the invite-only event for C-suite executives from the healthcare industry and government officials included Shaista Asif, Group Chief Executive Officer of PureHealth and Dr Michael Ringel, Managing Director of Boston Consulting Group, who discussed The Opportunity for Investment in Longevity Biotech. Meanwhile, panellists for the discussion on "The Longevity Economy: Navigating the Next Frontier" included Dr Yoshiki Sawa, Professor at Osaka University and Advisor to CiRA at Kyoto University; Prof Dr Evelyne Bischof, Founding Vice President of Healthy Longevity Medicine Society and Chair of the Scientific Advisory Board at Longevity Science Foundation; Marc P. Bernegger, Founding Partner of Maximon and Longevity Investors Conference. Closing remarks were made by Dr Fatima Al Kaabi, Director General, Emirates Drug Establishment and Executive Director of Abu Dhabi Bone Marrow Transplant Program at Abu Dhabi Stem Cells, a PureHealth subsidiary

Most Read

February 01, 2024 | Thursday

VitruvianMD secures $10,000 as winner of Arab Health’s Innov8 competition

VitruvianMD has won this year’s Arab Health Innov8 competition and, with it, a cash prize of $10,000, following an intensive week-long judging process that saw a total of 24 different companies pitch over the opening three days of Arab Health. VitruvianMD combine biomedical engineering and state-of-the-art artificial intelligence (AI) to deliver affordable, high-accuracy diagnostic tools for medical laboratories. At the core of VitruvianMD’s breakthrough technology is a versatile camera that seamlessly attaches to any microscope, empowered by sophisticated AI tools. This technology paves the way for laboratories to transition effortlessly into a digital pathology framework. In a world where diagnostician shortages remain an acute global challenge, particularly in regions like Sub-Saharan Africa with a concerning pathologist-to-population ratio, VitruvianMD’s solutions stand to set new standards. In addition to the US$10,000 top prize, VitruvianMD will have access to an exclusive mentorship program with Startupbootcamp MENA as well as the opportunity to engage in a series of discussions with potential investors to gain valuable insights and potentially secure new collaborations and raise funds. They will also be given free exhibition space at Arab Health 2025. The judging panel included a renowned number of investors, entrepreneurs and medical experts; among them were Triska Hamid, Editorial Director, Wamda; Hadi Saeed Alshakhori, Ecosystem Builder, of Saudi Arabia; Reenita Das, Top 100 women in Healthtech and Femtech, Partner, Senior Vice President, Frost & Sullivan; H.E. Faisal Belhoul, Vice Chairman, Dubai Chambers of Commerce & Industry, Founder and Chairman, Ithmar Capital Partners;Zeina Youseff, Operations Support Manager, Rainmaking; and, Dr Bader Khraibut, Senior Consultant, Strategy& Middle East, UAE Finalists included Hera Health Solutions, a pharmaceutical device company specialising in the research, development, and commercialisation of long-acting treatments through proprietary bioerodible drug delivery implants; Maya AI, an AI digital robot that connects data and creates next-step actions for specific workflows; and Incura Med, who are developing a range of technologies that offer high-performance and enhanced efficacy products and low-cost manufacturing. They were joined by Luminore Copper Touch, who hold the distinction of being the sole EPA-registered antimicrobial product that seamlessly adheres to virtually any surface; Nanopalm, the Saudi national start-up biotechnology company that creates next-generation nanomedicines for affordable and accelerated pharmaceutical R&D activities; Nephrodite, which has created a patient-inspired dialysis solution giving individuals greater health, increased mobility and the freedom to choose. Rounding out the finalists were Caresyntax, which offers a digital surgery platform that uses proprietary software and artificial intelligence (AI) to analyse large volumes of real-world data in and around the operating room (OR) to deliver insights that can be used immediately by the care team and longer-term by a variety of critical stakeholders. Elsewhere, on the final day of Arab Health 2024, the winners of the inaugural Cre8 competition were announced, with the team from the American University of Sharjah taking first prize for their Real-Time Wireless Monitoring System with Predictive Analysis of Healthcare Data. The team included Samrin Saleem, Rhea Srivastava, Ahmed Sharafath, and Nikita Miller. The competition was designed to foster creativity and innovation among participating students in the UAE were also announced. Contestants were required to conceptualise and innovate a solution for an actual healthcare problem within the confines of an imaginary AED 100,000 budget. The other finalists included Farah Adnan Ahmad Thugan, Lujain Adnan Ahmad Thugan, Asmaa Luai Abdulla Elbadawi, and Hala Anas Kahwajy from Ajman University for their classification of the stages of diabetic retinopathy; and Banan Dhafer Jumaah; Sedra Zulaikha, and Rawan Emad Refaie Ahmed, also from Ajman University, for their Chronic Respiratory Diseases (CRDs) ML and AI screening App. Judging the entries were Dr James Shapiro, Professor of Surgery, Medicine, and Surgical Oncology, University of Alberta; Carlos Iniguez, Director, GEN Accelerates; Sowmya Srinath, Director of Healthcare & Life Sciences, Frost & Sullivan; and Dr Louiza Chitour, Senior Advisor & Co-founder, Stealth Startup

January 30, 2024 | Tuesday

UAE healthcare authorities emphasise collaborative approaches and future priorities

UAE healthcare authorities, including the Ministry of Health and Prevention (MoHAP), Department of Health - Abu Dhabi (DOH), Dubai Health Authority (DHA), Abu Dhabi Health Services Company (SEHA), and Emirates Health Services (EHS) convened at Public Health Conference 2024 staged at Arab Health at the Dubai World Trade Centre from 29 – 30 January. International associations and health authorities represented at the Public Health Conference include the World Health Organisation, the Ministry of Health Singapore, the International Association for National Public Health Institutes, the International Hospital Federation, the Qatar Ministry of Public Health, and the Ministry of Health Kuwait. :Keynote Speeches: Dr Ramadan Alblooshi, Senior Advisor to the Director General of Dubai Health Authority at DHA, outlined how the COVID-19 pandemic has highlighted the importance of public health and created the demand for better funding investment in public health. “Worldwide, various public health sectors have strengthened their capabilities and infrastructure at different levels and developed the foundation of a global health risk framework management. Locally, in Dubai, we have adopted a chance at global, regional and national levels in developing public health and are moving forward for a better future of public health," he explained. Alblooshi also highlighted how there is an accelerated need for greater global public health partnerships and collaboration, with the DHA establishing strong relationships to support the Emirate's local public health work with the UK Health Security Agency (UKHSA), Centre for Disease Control and Prevention (CDC) and the Public Health Agency of Sweden, among others. Prof. Vernon Lee from the Ministry of Health Singapore discussed new approaches to surveillance and infectious diseases. At the same time, H.E. Dr Farida Al Hosani from the Abu Dhabi Public Health Centre gave an update on integrated surveillance for respiratory infections.  Ross Williams, Exhibition Director for Informa Markets, said: “This collaborative effort underscores our collective commitment to addressing pressing global health challenges. As we convene over the next few days, we eagerly anticipate the fruitful discussions and exchange of insights that will undoubtedly shape the future of public health in our region.” Uniting public health professionals to forge better public health practices in the UAE: The Public Health Conference called for experts to work together to accelerate the journey towards a healthier nation. During the two-day conference, attendees participated in interactive topics, including healthier lifestyle and behaviour change, occupational and environmental health, innovation and sustainability in public health, and best practices on crisis and disaster management. The DHA has identified critical public health priority areas for 2024 and beyond, including genomes, mental health, occupational health, non-communicable diseases, pandemics, climate change and people of determination. In additon, Emergency Medicine Conference, hosted valuable discussions around equitable healthcare and minimum best standards in different economic settings in the emergency and critical care departments, while the Surgery Conference outlined surgical advancements, emphasising innovative techniques, evolving practices, and the promising horizon of medical artificial intelligence. Medical professionals attending the exhibition had access to 10 Continuing Medical Education (CME) conferences, including other areas such as total radiology, diabetes, obstetrics and gynaecology, orthopaedics, quality management, and infection control and Central Sterile Supply Department (CSSD).

February 01, 2024 | Thursday

23rd Medlab Middle East to spotlight NextGen Medicine in international pavilions_5-8 Feb 2024

Medlab Middle East, the MENA region’s largest laboratory exhibition and congress, returns to the Dubai World Trade Centre next week from 5-8 February. This year’s event will feature 900 exhibitors from more than 40 countries, representing a 20% increase in exhibitors from last year.  Now in its 23rd year, Medlab Middle East is expected to be attended by more than 30,000 attendees. A key highlight for this edition is a newly introduced ‘NextGen Medicine Zone and Conference, which is hosted in partnership with Bahrain-based Express Med Diagnostics and Research. The innovative exhibition zone will showcase over 100 exhibitors and bring into focus a pioneering area in the medical laboratory field that aims to customise healthcare to individuals, using advanced technologies and new developments in medical science.  Taking place from 5 to 6 February, the NextGen Medicine Conference will explore topics including early cancer detection, precision oncology, preventative health screening, longevity, developments in cancer genetics and oncogenomics as well as updates on Middle East genome projects. The conference will also explore the digitalisation aspects of NextGen Medicine which includes Artificial Intelligence (AI), bioinformatics, and the cybersecurity of data.  The headline partner for the NextGen Medicine zone is Medsol, while the Premium partner is biosytech Medical Laboratory. Other exhibitors in the zone include Virtus, Purelab, Leader Life Sciences and Naizak. Attendees can stay up to date with the latest insights and innovations in NextGen Medicine at expert-led industry workshops. Running from 5-7 February, the industry workshops are sponsored by Akoya Biosciences, nanoString, LaboShop, Atila BioSystems, biosytech, BioSkyrb and Nanopore Technologies.  Addressing the upcoming edition of Medlab Middle East, Tom Coleman, Exhibition Director for Informa Markets, said: “Medlab Middle East provides a unique platform for the laboratory industry to showcase innovative products, state-of-the-art services, and cutting-edge solutions in a central global hub. One of the most exciting features of this year's exhibition is the NextGen Medicine Zone and Conference, which promises to be a game-changer in the field. This groundbreaking zone will bring together experts from around the world who will share the latest scientific advancements, providing a unique opportunity for industry professionals to learn and explore new possibilities.” Medlab Middle East Congress, the region’s only multi-disciplinary congress, returns for another year. Offering 12 CME-accredited live in-person conferences throughout the four-day exhibition, the congress features over 130 speakers and 150 sessions, with over 4,000 delegates expected.  NextGen Medicine and Clinical Genomic Interpretation are new additions to the Medlab Middle East congress this year, with returning tracks including Laboratory Management, Lab Quality Management, Clinical Chemistry, Immunology, Haematology, Clinical Microbiology, Blood Transfusion Medicine, Histopathology, Future of Lab and Sustainability in the Lab.  In line with its long-term sustainability goals, Medlab Middle Middle East has introduced the Better Stands Programme, which aims to encourage exhibitors and their appointed contractors to create reusable, recyclable structures that have a life cycle beyond just a single event. Through a unified approach to sustainability, it is hoped that this initiative will reduce waste and lower the carbon footprint of the exhibition.  Innovation will also take centre stage at Labpreneur, Medlab Middle East’s annual start-up competition. Held on the last day of the exhibition, Labpreneur features 10 shortlisted start-ups that have created revolutionary concepts for the medical laboratory field. The winner of the competition will receive complimentary stand space for Medlab Middle East 2025 along with a prestigious award.  Fostering the talents of future scientists, Medlab Middle East will host the second edition of LabQ, an inter-college quiz competition for senior graduating college and university students majoring in medical laboratory sciences in the UAE.  The competition focuses on pathology and laboratory medicine and will host students from the University of Sharjah, Liwa College, the Higher Colleges of Technology and Gulf Medical University.  The Scientific Poster Competition returns this year, with the winner receiving a research grant of a value up to USD 3,000. Elsewhere, attendees can expand their knowledge of the medical laboratory industry at the Medlab Partners Forum, which includes a think tank session from global research firm Frost & Sullivan and an insightful presentation from The Royal College of Pathologists on ‘The Global Challenge of Antimicrobial Resistance’.  Medlab Middle East will exhibit eight specialised product categories which include Disposables, Healthcare/General Services, Imaging, Infrastructure, IT, Laboratory, Medical Equipment and Pharma/Nutrition. Attendees will have the chance to explore the latest laboratory technologies from every corner of the globe with dedicated country pavilions from China, Taiwan, Brazil, Finland, Poland, the USA, Spain, Korea, Italy, Egypt and the UK.  Medlab Middle East takes place in Za’abeel Halls 1-7 at the Dubai World Trade Centre and will showcase industry leaders such as Abbott, Randox, Al Borg Diagnostics, Beckman Coulter and Sysmex.

January 30, 2024 | Tuesday

Experts advocate HPV Vaccination Programmes for Gynaecologic Cancer prevention in MENA region

The 16th Obstetrics and Gynaecology Conference took place on 30 January under the theme ‘From evidence to practice: Transforming obstetrics and gynaecology care through clinical case integration’. The two-day event equips health professionals from around the Middle East with the latest insights on various topics including Hormone Replacement Therapy, adolescent gynaecological issues and pregnancy loss and showcases the latest innovations that are transforming women’s health. HPV Vaccines and their role in preventing gynaecologic cancers are in focus at the Obstetrics and Gynaecology Conference, which is currently taking place at Arab Health 2024. HPV Vaccines and their role in preventing gynaecologic cancers According to a study by Global Cancer Statistics conducted in 2020, cervical cancer numbers are increasing worldwide, and it is now the fourth most common cancer in women. That same year, cervical cancer accounted for an estimated 604,000 new cancer cases worldwide and 342,000 deaths, and the study showed that 84% of cervical cancer cases were from regions where no screening programmes were available. Alarmingly, women in resource-limited countries are most likely to be affected, with cervical cancer being the second most common cancer and the third most common cause of cancer mortality in these regions. The Human Papillomavirus (HPV) is a sexually transmitted disease that is responsible for the majority of cervical cancers. The virus causes cervical neoplasia, which is classified into three stages; CIN1, CIN2, and CIN3. HPV is detected in 99.7% of cervical cancers, and it can take over ten years for cervical cancer to develop after contracting HPV. The HPV vaccine was introduced in 2007. There a three types of HPV vaccine that are currently available – the HPV Quadrivalent vaccine (Gardasil) which targets HPV types 6, 11, 16 and 18; HPV 9-valent (Gardasil 9) which targets HPV 31, 33, 45, 52 and 58 in addition to HPV 6, 11, 16 and 18 and HPV bivalent (Cervarix) which has been created to prevent HPV 16 and 18. Demonstrating the significant impact of the HPV Quadrivalent vaccine, two large randomised, double-blind trials found that the vaccine prevented CIN2 by 97-100% among HPV naïve populations. According to experts, if vaccine rates of 70% are achieved internationally, there would be an estimated decrease of over 300,000 new cases of cervical cancer annually and over 178,000 cervical cancer-related deaths. In 2016, the World Health Organisation (WHO) Strategic Advisory Group of Experts on Immunisation recommended that all girls should be vaccinated to prevent cervical cancer later in life. The WHO believes that to end cervical cancer, nine out of ten girls around the world should be vaccinated.   Promoting successful HPV vaccination programs worldwide, especialy in Asia and MENA: Dr Stephanie Ricci, MD, from Cleveland Clinic Abu Dhabi’s Gynaecology and Oncology departments, shared insights from successful HPV vaccination programs worldwide and highlighted the importance of adopting a similar approach in the MENA region.  “Thankfully, we have a vaccination for HPV, and there are successful national HPV programmes around the world that are almost a decade into their existence. The data from this is very interesting and compelling when it comes to gynaecologic cancer prevention,” said Dr Stephanie Ricci, MD, Staff Physician in gynaecology and oncology at Cleveland Clinic Abu Dhabi. “Australia has probably the most robust vaccination of any country in the world, and they’ve also had the most success. From 2007, Australia implemented school-based routine vaccination for 12-13-year-old girls, they then also did a catchup programme for 14-26-year-old females.  In 2013, Australia started vaccinating 12-13-year-old boys routinely in schools and rolled out a catchup programme for boys aged 14-15 years old. Australia, unlike many other countries that have employed HPV vaccination programmes, is actually going to eliminate cervical cancer” said Dr Ricci. Amid rising HPV vaccination rates, Australia is on track to eliminate cervical cancer by 2035. Five to eight years after the HPV vaccination was introduced to the country, the Australian Institute of Health and Welfare reported a 92% reduction in the HPV infection rate and a 47% decline in CIN2 and 3. There was also a significant reduction in excisional procedures.  

January 29, 2024 | Monday

“Arab Health_2024" Healthcare Trade Show exhibits Groundbreaking Technology and Transformative Products

The 2024 edition of the Arab Health, the largest healthcare exhibition in the MENA region, is holding its 49th edition in Dubai World Trade Centre, with the largest exhibition space to date. In addition to 3,450 exhibitors, 110,000 healthcare professionals representing 180 countries across the globe are attending the event. Under the show theme of ‘Connecting Minds, Transforming Healthcare’, Arab Health, the largest gathering of healthcare professionals and businesses in the MENA region, is holding more than 51,000 attendees during the four-day healthcare showcase, at the Dubai World Trade Centre from 29 January – 1 February.  The Arab Health Congress features ten Continuing Medical Education (CME) conferences dedicated to over 23,600 professional healthcare visitors, that comprise 330 expert speakers during over 165 sessions. His Highness Sheikh Maktoum bin Mohammed bin Rashid Al Maktoum, First Deputy Ruler of Dubai and Deputy Prime Minister and Minister of Finance of the UAE, has officially opened the Arab Health Exhibition and Congress 2024 today, Monday, 29 January. Ross Williams, Exhibition Director for Informa Markets, stated: “Arab Health's standing as the premier healthcare trade show in the region is based on its comprehensive approach, global reach, unwavering commitment to innovation, and the opportunities it provides for learning, networking, and collaboration within the healthcare sector – ultimately delivering the ultimate healthcare experience. "With a sharp focus on groundbreaking technology and transformative products enhancing patient care, the next four days promise to be a catalyst for the future of healthcare in the region and on a global scale. This impact is amplified by our international reach and the exceptional calibre of exhibitors showcased, making it a game-changing event for the industry worldwide." Dr Ramadan Al Balooshi from Dubai Health Authority outlined a vision for a ‘New Era of Public Health’ during the opening session at the Public Health Conference, while the World Health Organisation’s (WHO) Tan Sri Dr Noor Hisham Abdullah, highlighted the lessons learnt during COVID-19 and the importance of leadership. Arab Health 2024 is supported by various government entities, including the UAE Ministry of Health and Prevention, the Government of Dubai, the Dubai Health Authority, the Department of Health, and the Dubai Healthcare City Authority.  PureHealth, a National Healthcare Champion, American Hospital, an exclusive healthcare partner, Dr Sulaiman Al Habib, Emirates Health Services, a Global health partner, M2, a Future health partner, Neom, a Technology partner, and an Artificial Intelligence partner, Canon Medical, are among the key partners.


Asia Photonics Expo 2024 (APE)

Marina Bay Sands Expo and Convention Centre, Singapore

© Copyright 2024, MM Activ Sci-Tech Communications. All Rights Reserved.

Website Design & Developed By : SCI Knowledge Interlinks